骨髓增殖性肿瘤合并内脏静脉血栓患者的分子特征与风险分类
该回顾性研究纳入80例骨髓增殖性肿瘤合并内脏静脉血栓(MPN-SVT)患者,中位随访11年,主要终点为演变为骨髓纤维化、急性白血病或死亡。JAK2V617F等位基因负荷≥50%及染色质/剪接体基因额外突变与主要终点相关,高风险患者无事件生存率和10年总生存率均低于低风险患者,结果在30例独立验证队列中证实。
要点
- MPN-SVT患者中,JAK2V617F等位基因负荷≥50%与主要终点相关(OR 14.7)。
- 染色质/剪接体基因额外突变与主要终点相关(OR 9)。
- 高风险患者10年无事件生存率81% vs 低风险100%(P = .001),10年总生存率89% vs 100%(P = .01)。
核心结论
- 分子特征可识别预后不良的MPN-SVT患者。
- 在高风险人群中,应考虑疾病修饰治疗以降低转化概率。
研究设计与样本
- 回顾性研究,测试队列纳入80例经充分表征的MPN-SVT患者,中位随访11年。
- 另设30例MPN-SVT患者的独立验证队列。
主要发现
- 测试队列中13%的患者达到主要终点(演变为骨髓纤维化、急性白血病或死亡)。
- JAK2V617F等位基因负荷≥50%与主要终点相关(OR 14.7)。
- 染色质/剪接体基因额外突变与主要终点相关(OR 9)。
- 高风险患者(占队列29%)定义为至少携带1项分子危险因素:JAK2突变等位基因负荷≥50%、染色质/剪接体/TP53突变。
- 高风险患者10年无事件生存率81% vs 低风险患者100%(P = .001),10年总生存率89% vs 100%(P = .01);结果在30例独立验证队列中证实。
关键数值与推荐
- 高风险定义:至少携带1项分子危险因素,即JAK2突变等位基因负荷≥50%、染色质/剪接体/TP53突变。
- 主要终点:演变为骨髓纤维化、急性白血病或死亡。
临床怎么用
- 作者认为,在高风险MPN-SVT人群中应考虑疾病修饰治疗以降低转化概率。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Myeloproliferative neoplasms (MPNs) are the most frequent underlying causes of splanchnic vein thromboses (SVTs). MPN patients with SVTs (MPN-SVT) often have a unique presentation including younger age, female predominance, and low Janus kinase 2 (JAK2) mutation allele burden. This study aimed at identifying risk factors for adverse hematologic outcomes in MPN-SVT patients. We performed a retrospective study of a fully characterized cohort of MPN-SVT patients. The primary outcome was the incidence of evolution to myelofibrosis, acute leukemia, or death. Eighty patients were included in the testing cohort. Median follow-up was 11 years. Most of the patients were women with a mean age of 42 years and a diagnosis of polycythemia vera. The primary outcome was met in 13% of the patients and was associated with a JAK2V617F allele burden ≥50% (odds ratio [OR], 14.7) and presence of additional mutations in genes affecting chromatin/spliceosome (OR, 9). We identified high-risk patients (29% of the cohort) as those harboring at least 1 molecular risk factor: JAK2-mutant allele burden ≥50%, presence of chromatin/spliceosome/TP53 mutation. High-risk patients had worse event-free survival (81% vs 100%; P = .001) and overall survival at 10 years (89% vs 100%; P = .01) than low-risk patients. These results were confirmed in an independent validation cohort of 30 MPN-SVT patients. In conclusion, molecular profiling identified MPN-SVT patients with dismal outcome. In this high-risk population, a disease-modifying therapy should be taken into consideration to minimize the probability of transformation.
引用
- Debureaux PE, Cassinat B, Soret-Dulphy J, et al. Molecular profiling and risk classification of patients with myeloproliferative neoplasms and splanchnic vein thromboses. Blood Adv. 2020. PMID: 32777065. doi:10.1182/bloodadvances.2020002414
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。